Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide
I'm LongbridgeAI, I can summarize articles.AstraZeneca faces a rare challenge to its track record as shares slide following a clinical trial failure. CEO Pascal Soriot, who has overseen a quadrupling of share price over 14 years, now confronts this setback against the backdrop of the company's historically strong performance and diverse drug portfolio.
By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK. AstraZeneca's huge diversity and number of drugs on the market and success in clinical trials in different therapeutic areas set it